Refractory secondary thrombotic microangiopathy with kidney injury associated with systemic lupus erythematosus in a

Tomoya Kaneda1, Eriko Tanaka2,3, Yuko Akutsu1

  • 1Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.

CEN Case Reports
|April 19, 2020
PubMed

Insights

This case study details a rare instance of severe juvenile systemic lupus erythematosus (SLE) with thrombotic microangiopathy (TMA) and kidney injury. Effective treatment involved a combination of immunosuppressants and plasma exchange, highlighting a complex therapeutic challenge.

Area of Science:

  • Nephrology
  • Rheumatology
  • Pediatric Autoimmunity

Background:

  • Thrombotic microangiopathy (TMA) is a serious condition characterized by hemolytic anemia, low platelets, and organ damage.
  • Systemic lupus erythematosus (SLE) can lead to secondary TMA, often with a poor prognosis, especially in pediatric cases.

Observation:

  • A 5-year-old patient presented with severe juvenile-onset SLE complicated by TMA and significant kidney injury.
  • Clinical features included renal dysfunction, thrombocytopenia, hemolytic anemia, nephrotic syndrome, hypocomplementemia, and elevated anti-dsDNA antibodies.
  • Kidney biopsy showed characteristic lupus nephritis with TMA findings, including endothelial cell changes and immune deposits.

Findings:

  • Combination therapy with methylprednisolone, mycophenolate mofetil, and plasma exchange proved effective.
  • Eculizumab was ineffective, but subsequent addition of intravenous cyclophosphamide successfully controlled the disease.
  • Whole-exome sequencing did not reveal genetic mutations linked to complement disorders or type-1 interferon pathways.

Implications:

  • This case underscores the severe manifestations of TMA in juvenile SLE and the challenges in treatment.
  • Aggressive immunosuppressive therapy, including cyclophosphamide, may be crucial for managing refractory cases.
  • Further research into the pathogenesis of juvenile SLE-TMA is essential for developing targeted therapies.

Related Concept Videos

Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
734
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
426
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
404
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
662
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
222